Metabolic
Setmelanotide
Also called Imcivree, RM-493
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US and EU.
Quick start
Setmelanotide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 0.5–3 mg per administration
- How often
- Every day
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~2.3 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Setmelanotide describe 0.5–3 mg per administration. Descriptive only, not a recommendation.
Dosing schedule
How Setmelanotide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–2Lower start; step up by 0.5 mg no sooner than every 2 weeks. | 0.5–1 mg | Once daily | SubQ |
| Titration | +0.5 mg every 2 weeks | Once daily | SubQ |
| MaximumHighest step reported; reached only as tolerated. | 3 mg | Once daily | SubQ |
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.28× single dose
- Time to steady state
- 2.3days
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Clément K et al., Lancet Diabetes Endocrinol 2020;8:960Phase-3, open-label study of the MC4R agonist setmelanotide, titrated by 0.5 mg to as much as 3 mg once daily, in severe obesity from POMC or LEPR deficiency.